Invitrogen

Human TMEM184B (aa 343-407) Control Fragment Recombinant Protein

Product Details

RP-92365

Applications

Tested Dilution

Publications

Control (Ctrl)

Assay-dependent

Blocking Assay (BLOCK)

Assay-dependent

Product Specifications

Species

Human

Expression System

E. coli

Amino acid sequence

TMNPHDIVQDAIHNFSPAYQQYTQQSTLEPGPTWRGGAHGLSRSHSLSGARDNEKTLLLSSDDEF

Tag

His-ABP-tag

Class

Recombinant

Type

Protein

Purity

>80% by SDS-PAGE and Coomassie blue staining

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

≥5.0 mg/mL

Purification

purified

Storage buffer

1M urea/PBS, pH 7.4

Contains

no preservative

Storage conditions

-20°C, Avoid Freeze/Thaw Cycles

Product Specific Information

Highest antigen sequence indentity to the following orthologs: Mouse (97%), Rat (97%).

This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-54973. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.

Target Information

TMEM184B, also known as C22orf5, is a 407 amino acid multi-pass membrane protein and represents a novel gene in the activation of the MAPK signaling pathway. The gene encoding TMEM184B maps to human chromosome 22; mutations in several of the genes in chromosome 22 are involved in the development of autism, schizophrenia, Phelan-McDermid syndrome and Neurofibromatosis type 2, suggesting that TMEM184B may play a role in these syndromes.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

References (0)

Have you cited this product in a publication?

Let us know so we can reference it here.

Cite this product

Bioinformatics

Protein Aliases: CTA-447C4.2; Putative MAPK-activating protein FM08; Transmembrane protein 184B